Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THUNDER: Darolutamide in High-Risk Prostate Cancer
NCT06282588Phase 3Recruiting
- Sponsor
- Center for Oncological Research
- Start
- Dec 2023
- Primary completion
- Jul 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darolutamide in prostate cancer (PCa) (3 arms), sponsored by Center for Oncological Research. Primary endpoints: PSMA PET metastasis free survival at 42 months, Quality of life (sexual subdomain) at 12 months and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06282588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282588.